Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LNTH Lantheus	$74.41 -8.4%	$79.17	$69.12 ▼ $122.83	$5.62B	0.12	975,618 shs	4.16 million shs
NUVL Nuvalent	$85.45 +3.0%	$76.66	$55.54 ▼ $113.51	$5.96B	1.31	505,973 shs	411,295 shs
SDGR Schrodinger	$21.25 +4.3%	$22.03	$16.60 ▼ $28.47	$1.49B	1.58	919,229 shs	1.06 million shs
TGTX TG Therapeutics	$38.84 +2.3%	$36.22	$16.65 ▼ $46.48	$6.03B	1.91	2.85 million shs	1.86 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LNTH Lantheus	-8.43%	-10.88%	-4.38%	-26.56%	-37.10%
NUVL Nuvalent	+3.01%	+4.85%	+11.96%	+19.28%	+1.71%
SDGR Schrodinger	+4.32%	-1.98%	+0.24%	-17.48%	-11.53%
TGTX TG Therapeutics	+2.32%	+2.43%	+9.01%	+1.36%	+72.47%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
LNTH Lantheus	4.5676 of 5 stars	3.4	2.0	4.2	2.8	2.5	1.9
NUVL Nuvalent	3.3331 of 5 stars	4.6	1.0	0.0	3.1	3.3	0.0
SDGR Schrodinger	1.796 of 5 stars	3.4	1.0	0.0	1.8	1.7	0.6
TGTX TG Therapeutics	3.5146 of 5 stars	2.4	0.0	3.5	2.2	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LNTH Lantheus	2.83	Moderate Buy	$131.20	76.32% Upside
NUVL Nuvalent	3.17	Buy	$119.60	39.96% Upside
SDGR Schrodinger	2.75	Moderate Buy	$32.75	54.12% Upside
TGTX TG Therapeutics	2.80	Moderate Buy	$43.80	12.77% Upside

Current Analyst Ratings Breakdown

Latest SDGR, TGTX, NUVL, and LNTH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	LNTH Lantheus	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
7/14/2025	SDGR Schrodinger	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$32.00 ➝ $30.00
7/10/2025	TGTX TG Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold	$37.00
7/3/2025	SDGR Schrodinger	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$28.00
6/30/2025	NUVL Nuvalent	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/25/2025	NUVL Nuvalent	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$105.00 ➝ $112.00
6/24/2025	NUVL Nuvalent	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$115.00
6/24/2025	NUVL Nuvalent	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$125.00 ➝ $140.00
6/24/2025	NUVL Nuvalent	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$110.00 ➝ $130.00
6/23/2025	LNTH Lantheus	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$122.00 ➝ $109.00
5/8/2025	LNTH Lantheus	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$127.00 ➝ $117.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LNTH Lantheus	$1.53B	3.36	$6.50 per share	11.45	$15.65 per share	4.75
NUVL Nuvalent	N/A	N/A	N/A	N/A	$14.99 per share	N/A
SDGR Schrodinger	$207.54M	7.51	N/A	N/A	$5.78 per share	3.68
TGTX TG Therapeutics	$329M	18.74	$0.12 per share	316.43	$1.43 per share	27.16

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LNTH Lantheus	$312.44M	$3.52	21.14	11.79	N/A	16.55%	36.99%	20.55%	7/30/2025 (Estimated)
NUVL Nuvalent	-$260.76M	-$4.39	N/A	N/A	N/A	N/A	-31.35%	-29.27%	8/14/2025 (Estimated)
SDGR Schrodinger	-$187.12M	-$2.63	N/A	N/A	N/A	-83.39%	-44.74%	-26.29%	7/30/2025 (Estimated)
TGTX TG Therapeutics	$23.38M	$0.24	161.83	38.84	N/A	10.13%	18.88%	7.05%	8/5/2025 (Estimated)

Latest SDGR, TGTX, NUVL, and LNTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	N/A	NUVL Nuvalent	-$1.27	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	TGTX TG Therapeutics	$0.27	N/A	N/A	N/A	$147.76 million	N/A
7/30/2025	Q2 2025	LNTH Lantheus	$1.65	N/A	N/A	N/A	$389.69 million	N/A
7/30/2025	Q2 2025	SDGR Schrodinger	-$0.83	N/A	N/A	N/A	$52.03 million	N/A
5/8/2025	Q1 2025	NUVL Nuvalent	-$1.14	-$1.18	-$0.04	-$1.18	N/A	N/A
5/7/2025	Q1 2025	LNTH Lantheus	$1.64	$1.53	-$0.11	$1.02	$377.37 million	$372.76 million
5/7/2025	Q1 2025	SDGR Schrodinger	-$0.81	-$0.82	-$0.01	-$0.82	$54.60 million	$59.55 million
5/7/2025	Q1 2025	TGTX TG Therapeutics	$0.19	$0.03	-$0.16	$0.03	$117.07 million	$120.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
NUVL Nuvalent	N/A	N/A	N/A	N/A	N/A
SDGR Schrodinger	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LNTH Lantheus	0.49	5.74	5.46
NUVL Nuvalent	N/A	14.48	14.48
SDGR Schrodinger	N/A	3.45	3.45
TGTX TG Therapeutics	1.03	4.02	3.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LNTH Lantheus	99.06%
NUVL Nuvalent	97.26%
SDGR Schrodinger	79.05%
TGTX TG Therapeutics	58.58%

Insider Ownership

Company	Insider Ownership
LNTH Lantheus	1.50%
NUVL Nuvalent	10.20%
SDGR Schrodinger	8.60%
TGTX TG Therapeutics	10.64%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LNTH Lantheus	700	69.19 million	68.15 million	Optionable
NUVL Nuvalent	40	71.81 million	64.48 million	Optionable
SDGR Schrodinger	790	73.38 million	67.07 million	Optionable
TGTX TG Therapeutics	290	158.76 million	141.86 million	Optionable

SDGR, TGTX, NUVL, and LNTH Headlines

Recent News About These Companies

Sigma Planning Corp Takes Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

3 hours ago | marketbeat.com

Bank of New York Mellon Corp Cuts Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

July 15 at 3:35 AM | marketbeat.com

TG Therapeutics (NASDAQ:TGTX) Upgraded to Hold at The Goldman Sachs Group

July 13, 2025 | americanbankingnews.com

TG Therapeutics (TGTX) Gets a Hold from Goldman Sachs

July 12, 2025 | theglobeandmail.com

Banque Pictet & Cie SA Acquires Shares of 13,151 TG Therapeutics, Inc. (NASDAQ:TGTX)

July 11, 2025 | marketbeat.com

TG Therapeutics Joins Rank Of Stocks With RS Ratings Over 90

July 10, 2025 | msn.com

TG Therapeutics Joins Elite List Of Stocks With 95-Plus Composite Rating

July 10, 2025 | msn.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Recommendation of "Moderate Buy" from Analysts

July 10, 2025 | marketbeat.com

TG Therapeutics (NASDAQ:TGTX) Earns Neutral Rating from Analysts at The Goldman Sachs Group

July 10, 2025 | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Position Increased by Allspring Global Investments Holdings LLC

July 9, 2025 | marketbeat.com

Axsome Therapeutics Sees Relative Strength Rating Climb To 79

July 8, 2025 | msn.com

Penserra Capital Management LLC Takes Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

July 8, 2025 | marketbeat.com

Principal Financial Group Inc. Increases Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

July 8, 2025 | marketbeat.com

New York State Teachers Retirement System Boosts Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

July 7, 2025 | marketbeat.com

Braun Stacey Associates Inc. Has $19.82 Million Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

July 5, 2025 | marketbeat.com

TG Therapeutics, Inc. (TGTX) - Yahoo Finance

July 3, 2025 | finance.yahoo.com

Jim Cramer on TG Therapeutics: “You Should Buy the Stock”

July 2, 2025 | insidermonkey.com

Kymera Therapeutics Shows Market Leadership With Jump To 93 RS Rating

July 2, 2025 | msn.com

Cramer's Lightning Round: TG Therapeutics is a buy

June 30, 2025 | nbcnewyork.comN

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by Illinois Municipal Retirement Fund

June 30, 2025 | marketbeat.com

TGTX - TG Therapeutics Inc Financials - Morningstar

June 28, 2025 | morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

SDGR, TGTX, NUVL, and LNTH Company Descriptions

Lantheus NASDAQ:LNTH

$74.41 -6.85 (-8.43%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$74.70 +0.30 (+0.40%)

As of 07:17 AM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Nuvalent NASDAQ:NUVL

$85.45 +2.50 (+3.01%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$85.35 -0.10 (-0.12%)

As of 07:08 AM Eastern

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Schrodinger NASDAQ:SDGR

$21.25 +0.88 (+4.32%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$21.32 +0.07 (+0.35%)

As of 07:25 AM Eastern

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

TG Therapeutics NASDAQ:TGTX

$38.84 +0.88 (+2.32%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$38.84 0.00 (0.00%)

As of 07:22 AM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time